Eisenthal A, Monselise J, Zinger R, Adler A
Cancer Immunol Immunother. 1986;21(2):141-7. doi: 10.1007/BF00199862.
The effect of cimetidine, an H-2 receptor antagonist, on activation of PBL from both normal individuals and melanoma patients was studied. It has been shown that cimetidine enhanced, though moderately, the production of TCGF from normal PBL after PHA-P stimulation. In addition, cimetidine significantly augmented TCGF-induced proliferation of normal PBL, as well as proliferation induced by allogeneic cells (MLC) by PPD, Con A, and PHA. In PBL samples where coincubation with cimetidine had limited or no effect, preincubation of PBL with cimetidine prior to the addition of IL-2 and other T cell activators showed a significant enhancement effect. This effect mediated by cimetidine was further demonstrated on PBL from melanoma patients whose T cell responses were initially low. The possibilities are discussed that: (a) cimetidine treatment inactivates suppressor cell activity, thus enhancing T cell mediated responses; or (b) cimetidine may act directly at effector cell level.
研究了H-2受体拮抗剂西咪替丁对正常人和黑色素瘤患者外周血淋巴细胞(PBL)激活的影响。结果表明,西咪替丁虽作用程度中等,但能增强PHA-P刺激后正常PBL中TCGF的产生。此外,西咪替丁显著增强了TCGF诱导的正常PBL增殖,以及PPD、Con A和PHA诱导的同种异体细胞(MLC)诱导的增殖。在与西咪替丁共孵育作用有限或无作用的PBL样本中,在添加IL-2和其他T细胞激活剂之前先用西咪替丁预孵育PBL,显示出显著的增强作用。西咪替丁介导的这种作用在初始T细胞反应较低的黑色素瘤患者的PBL上得到了进一步证实。讨论了以下可能性:(a)西咪替丁治疗使抑制细胞活性失活,从而增强T细胞介导的反应;或(b)西咪替丁可能直接作用于效应细胞水平。